Paradigm Biocapital Advisors LP
NEW YORK, NY · CIK 1855655 · 13F filing filed 2023-11-14
SEC-registered investment adviser since 2021 · limited partnership
- Assets managed$4.5bn
- Staff11 · 6 in investment roles
- Main clients (by assets)Private funds 90%
- Private funds2 (2 hedge) · $4.1bn gross assets
- Form ADV · 2026-08-27SEC adviser record
- Legal entityPARADIGM BIOCAPITAL ADVISORS LP (US)
- Kindhedge funds, futures
- Others nearbyNew York, NY
As an employer
- Offices in1 country
- Private fundshedge 2
$1.5bn
reported value
+18.6% vs Q2 2023
29positions
61.0%in top 10
6 new
19 added
3 reduced
6 sold out
vs Q2 2023
Options: 2 call positions ($7.5m notional), 0 put positions (— notional) – listed below, not included above.
Holdings, Q3 2023
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| LEGEND BIOTECH CORP LEGN | $136.1m9.28% | Added +219.8k |
| ARGENX SE ARGX | $128.5m8.77% | Added +119.2k |
| ARCELLX INC ACLX | $106.0m7.23% | Added +606.1k |
| OLEMA PHARMACEUTICALS INC OLMA | $96.4m6.57% | Added +4.1m |
| NUVALENT INC COM | $75.3m5.14% | Added +517.7k |
| BICYCLE THERAPEUTICS PLC BCYC | $73.2m4.99% | Added +1.7m |
| MIRATI THERAPEUTICS INC MRTX | $72.7m4.96% | Added +224.4k |
| IMMUNOCORE HLDGS PLC IMCR | $71.9m4.90% | Added +114.6k |
| UNITED THERAPEUTICS CORP DEL UTHR | $69.4m4.73% | Added +68.9k |
| CRINETICS PHARMACEUTICALS IN CRNX | $64.8m4.42% | Added +783.7k |
| DISC MEDICINE INC IRON | $59.8m4.08% | New |
| VIRIDIAN THERAPEUTICS INC VRDN | $56.5m3.85% | Added +1.3m |
| CEREVEL THERAPEUTICS HLDNG I CERE | $55.3m3.77% | Added +664.0k |
| INCYTE CORP INCY | $52.7m3.60% | Reduced -469.2k |
| XENON PHARMACEUTICALS INC XENE | $51.0m3.48% | Added +502.5k |
| AMBRX BIOPHARMA INC SPONSORED ADS | $40.1m2.74% | Added +1.8m |
| SYNDAX PHARMACEUTICALS INC SNDX | $34.7m2.37% | Reduced -34.1k |
| AUTOLUS THERAPEUTICS PLC AUTL | $33.6m2.29% | Added +5.2m |
| TG THERAPEUTICS INC TGTX | $30.3m2.06% | New |
| ZAI LAB LTD ZLAB | $27.8m1.89% | Added +277.1k |
| ALPINE IMMUNE SCIENCES INC NVLS | $27.7m1.89% | Reduced -2.2k |
| IMMATICS N.V IMTX | $23.8m1.63% | Added +73.6k |
| VERONA PHARMA PLC VRNA | $15.1m1.03% | Added +32.6k |
| CARIBOU BIOSCIENCES INC CRBU | $14.1m0.96% | New |
| VOR BIOPHARMA INC COM | $13.7m0.93% | Unchanged |
| ROIVANT SCIENCES LTD ROIV | $12.6m0.86% | New |
| KURA ONCOLOGY INC KURA | $11.1m0.75% | Added +207.9k |
| COMPASS PATHWAYS PLC CMPS | $10.1m0.69% | New |
| COGENT BIOSCIENCES INC COGT | $2.2m0.15% | New |
Sold out since Q2 2023
| Security | Value then |
|---|---|
| KARUNA THERAPEUTICS INC | $61.5m283.6k shares |
| BEIGENE LTD ONC | $38.5m216.1k shares |
| VIR BIOTECHNOLOGY INC VIR | $24.9m1.0m shares |
| MADRIGAL PHARMACEUTICALS INC MDGL | $19.6m85.0k shares |
| MOONLAKE IMMUNOTHERAPEUTICS MLTX | $18.9m369.6k shares |
| THESEUS PHARMACEUTICALS INC | $18.2m2.0m shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| 89BIO INC ETNB · Call | $5.1m329.1k shares | New |
| AMBRX BIOPHARMA INC Call | $2.4m209.6k shares | New |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| OLEMA PHARMACEUTICALS INC OLMA · 13G · filed 2025-02-14 | 10.0%≈ $92.9m |
| EDGEWISE THERAPEUTICS INC EWTX · 13G · filed 2026-08-14 | 9.5%≈ $415.1m |
| ACHIEVE LIFE SCIENCES INC ACHV · 13G · filed 2026-04-24 | 9.2%≈ $64.7m |
| ASSEMBLY BIOSCIENCES INC ASMB · 13G · filed 2026-08-14 | 7.8%≈ $42.7m |
| VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 | 6.1%≈ $123.5m |
| TYRA BIOSCIENCES INC TYRA · 13G · filed 2026-09-17 | 5.8%≈ $110.9m |
| LEXEO THERAPEUTICS INC LXEO · 13G · filed 2026-08-14 | 5.3%≈ $19.4m |
| MBX BIOSCIENCES INC MBX · 13G · filed 2026-06-24 | 5.2%≈ $137.6m |
| SPYRE THERAPEUTICS INC SYRE · 13G · filed 2026-10-01 | 5.1%≈ $395.7m |
| JADE BIOSCIENCES INC JBIO · 13G · filed 2026-07-17 | 5.1%≈ $69.0m |